The Department of Justice notified Boeing and the federal court that Boeing breached its January 2021 deferred prosecution agreement by failing to maintain the required compliance and ethics program. The finding came after the January 5, 2024 Alaska Airlines door plug blowout revealed that Boeing …
Department of JusticeBoeingFederal District CourtCriminal Division Fraud Section346 crash victims' familiesboeingdojdeferred-prosecutionalaska-airlinesdoor-plug+2 more
On February 25, 2022, Johnson & Johnson and three major drug distributors—McKesson, Cardinal Health, and AmerisourceBergen—finalized a $26 billion national settlement to resolve thousands of opioid lawsuits from states, counties, cities, and Native American tribes. Despite the record settlement …
The Department of Justice charged Boeing with one count of conspiracy to defraud the United States in connection with the 737 MAX evaluation and entered a deferred prosecution agreement requiring Boeing to pay $2.5 billion in penalties. Despite evidence that Boeing executives knowingly deceived the …
Department of JusticeBoeing346 crash victimsVictims' familiesCriminal Division Fraud Sectionboeingdeferred-prosecutioncorporate-crimeimpunity737-max+2 more
On October 21, 2020, the Department of Justice announced a settlement totaling more than $8 billion with Purdue Pharma—touted as the largest penalties ever levied against a pharmaceutical manufacturer—yet the settlement allowed the Sackler family to keep the vast majority of billions extracted from …
U.S. Department of JusticePurdue PharmaSackler FamilyRichard SacklerDavid Sackler+4 moreopioid-crisiscorporate-crimeaccountability-failuredeferred-prosecutionwealth-extraction
Wells Fargo agrees to pay $3 billion to resolve criminal and civil investigations by the Department of Justice and Securities and Exchange Commission into sales practices that created millions of unauthorized accounts between 2002 and 2016. In a deferred prosecution agreement, Wells Fargo formally …
Wells FargoDepartment of JusticeSecurities and Exchange Commissioncorporate-fraudwells-fargodojdeferred-prosecution
On May 10, 2007, Purdue Pharma pleaded guilty to a felony charge of illegally misbranding OxyContin in an effort to mislead and defraud physicians and agreed to pay $600 million—representing approximately 90 percent of OxyContin profits during the offense period. The company admitted to misleading …
Purdue PharmaMichael FriedmanHoward R. UdellPaul D. GoldenheimU.S. Department of Justiceopioid-crisiscorporate-crimeaccountability-failuredeferred-prosecutionregulatory-capture+1 more